Abstract
Insulin-like growth factor (IGF-1) is a polypeptide of 70 amino acids. The circulatory form of IGF-1 is synthesised in the liver. The metabolic activity of IGF-1 is regulated by 6 IGF-binding proteins (BPs), the most important being IGFBP-3. IGF-1 acts via its own receptor, which resembles that of insulin. It has been demonstrated that the effects of growth hormone (GH) on protein metabolism, including growth and the effect on nerve tissue versus trophic effects, are mediated by IGF-1, whereas these 2 hormones are antagonistic in their effects on insulin and some aspects of lipid metabolism. This paper reviews present knowledge on the physiological role of IGF-1 and clinical effects of recombinant IGF-1 (somatomedin-1).
The biosynthesis of somatomedin-1 in 1986 enabled the initiation of clinical trials. Somatomedin-1 has many potential uses in the clinic. The most important is replacement therapy in primary IGF-1 deficiency, such as Laron syndrome (primary GH resistance or insensitivity) and in patients who have developed antibodies to hGH. In Laron syndrome, which is characterised by dwarfism, somatomedin-1 stimulates growth and increases muscle and bone mass, as well as normalising blood chemistry. In types 1 and 2 (insulin-dependent and non—insulin-dependent) diabetes mellitus, somatomedin-1 increases the sensitivity to insulin and improves glucose utilisation.
Experimental studies indicate that IGF-1 has a role in nerve tissue metabolism, and in humans may contribute to healing of injured nerve tissue. Other current clinical trials using the anabolic properties of somatomedin-1 are studying its effect on osteoporosis, catabolic states (burns, post-operation, AIDS) and haematopoietic disorders. Adverse effects of somatomedin-1 appear to be related to overdosage.
In conclusion, somatomedin-1 is an important hormone which has a promising role as replacement therapy and appears to have many other potential applications in the clinic.
Similar content being viewed by others
References
Merimee T, Laron Z. Growth hormone, IGF-I and growth: New views of old concepts. London-Tel Aviv: Freund Publishing House Ltd, Mod Endocrinol Diabetes 1996
Blundell TL, Humbel RE. Hormone families: pancreatic hormones and homologous growth factors. Nature 1980; 287: 781–7
Rinderknecht E, Humbel RE. The amino acid sequence of human insulin like growth factor I and its structural homology with proinsulin. J Biol Chem 1978; 253: 2769–76
Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995; 16: 3–34
Zapf J, Gosteli-Peter M, Schmid C. Insulin-like growth factor binding proteins (IGFBPs). In: Merimee T, Laron Z, editors. Growth hormone, IGF-I and growth: new views of old concepts. London-Tel Aviv: Freund Publishing House Ltd.,Mod Endocrinol Diabetes 1996: 45–71
Kaneti H, Silbergeld A, Klinger B, et al. Long-term effects of insulin-like growth factor (IGF)-I on serum IGF-I, IGF-binding protein-3 and acid labile subunit in Laron syndrome patients with normal growth hormone binding protein. Eur J Endocrinol 1997; 137: 626–30
LeRoith D, Werner H, Beitner-Johnson D, et al. Molecular biology of IGF-I receptor. In: Merimee T, Laron Z, editors. Growth hormone, IGF-I and growth: new views of old concepts. London-Tel Aviv: Freund Publishing House Ltd.,Mod Endocrinol Diabetes 1996: 73–99
Adamo ML. Regulation of insulin-like growth factor I gene expression. Diabetes Rev 1995; 3: 2–27
Bach LA, Rechler MM. Insulin-like growth factor binding proteins. Diabetes Rev 1995; 3: 38–61
Silbergeld A, Litwin A, Bruchis S, et al. Insulin-like growth factor (IGF-I) in healthy children, adolescents and adults as determined by a radioimmunoassay specific for the synthetic 53-70 peptide region. Clin Endocrinol 1986; 25: 67–74
Guler HP, Zapf J, Schmid C, et al. Insulin like growth factors I and II in healthy man. Estimations of half lives and production rates. Acta Endocrinol 1989; 121: 753–8
Laron Z. Prismatic cases: Laron Syndrome (primary growth hormone resistance). From patient to laboratory to patient. J Clin Endocrinol Metab 1995; 80: 1526–73
Phillips LS, Unterman TG. Somatomedin activity in disorders of nutrition and metabolism. In: Daughaday WH, editor. Clinics in endocrinology and metabolism: tissue growth factors. London: WB Saunders 1984: 145–89
Niwa M, Sato Y, Saito Y, et al. Chemical synthesis, cloning and expression of genes for human somatomedin C (insulin like growth factor I) and 59Val somatomedin C. Ann NY Acad Sci 1986; 469: 31–52
Laron Z. Somatomedin I in clinical use: facts and potential. Drugs 1993; 45: 1–8
Clemmons DR, Underwood LE. Clinical review 59. Uses of human insulin-like growth factor-I in clinical conditions. J Clin Endocrinol Metab 1994; 79: 4–6
Zapf J. Insulin-like growth factor (IGF)-I: an alternative for growth hormone (GH)? Int Growth Monit 1996; 6: 2–6
Guler HP, Zapf J, Froesch ER. Short term metabolic effects of recombinant human insulin like growth factor in healthy adults. N Engl J Med 1987; 317: 137–40
Froesch ER, Guler HP, Schmid C, et al. Therapeutic potential of insulin-like growth factor I. Trends Endocrinol Metab 1990; 1: 254–60
Elahi D, McAloon-Dyke M, Fukagawa NK, et al. Hemodynamic and metabolic responses to human insulin like growth factor (IGF-I) in men. In: Spencer M, editor. Modern concepts of insulin like growth factor. Asterdam: Elsevier Science, 1991: 219–24
Zenobi PD, Graf S, Froesch ER. Effects of recombinant human insulin like growth factor I (rIGF-I) infusion on glucose tolerance, insulin levels and insulin secretion in man. [abstract no. 45]. Diabetes 1991; 40(Suppl. 1): 12A
Takano K, Hizuka N, Asakawa K, et al. Effects of s.c. administration of recombinant insulin like growth factor I (IGF-I) on normal human patients. Endocrinol Jpn 1990; 37: 309–17
Takano K, Hizuka N, Shizume K, et al. Repeated s.c. administration of recombinant insulin like growth factor I (IGF-I) to human patients for 7 days. Growth Regul 1991; 1: 23–8
Laron Z, Klinger B, Erster B, et al. Effects of acute administration of insulin like growth. factor I in patients with Laron-type dwarfism. Lancet 1988; ii: 1170–2
Laron Z, Klinger B, Silbergeld A, et al. Intravenous administration of recombinant IGF-I lowers serum GHRH and TSH. Acta Endocrinol 1990; 123: 378–82
Laron Z, Blum W, Chatelain P, et al. Classification of growth hormone insensitivity syndrome. J Pediatr 1993; 122: 241
Rosenfeld RG, Rosenbloom AL, Guevarra-Aguirre J. Growth hormone (GH) insensitivity to primary Gh receptor deficiency. Endocr Rev 1994; 15: 369–90
Klinger B, Garty M, Silbergeld A, et al. Elimination characteristics of intravenously administered rIGF-I in Laron type dwarfs (LTD). Dev Pharmacol Ther 1990; 15: 196–9
Eshet R, Dux Z, Silbergeld A, et al. Erythrocytes from patients with low serum concentrations of IGF-I have an increase in receptor sites for IGF-I. Acta Endocrinol (copenh) 1991; 125: 354–8
Eshet R, Klinger B, Silbergeld A, et al. Modulation of insulin like growth factor I (IGF-I) binding sites on erythrocytes by IGF-I treatment in patients with Laron syndrome (LS). Regul Pept 1993; 48: 233–9
Laron Z, Klinger B, Blum WF, et al. IGF binding protein 3 in patients with LTD: effect of exogenous rIGF-I. Clin Endocrinol 1992; 36: 301–4
Gourmelen M, Perin L, Binoux M. Interest of IGF-I and IGF-BPs measurements in patients with Laron-type dwarfism. In: Laron Z, Parks JS, editors. Lessons from Laron Syndrome (LS) 1966-1992. Bsel-New York: Karger, 1993: 181–184. Pediatric and Adolescent Endocrinology, vol. 24.
Gil-Ad I, Koch Y, Silbergeld A, et al. Differential effect of insulin-like growth factor I (IGF-I) and growth hormone (GH) on hypothalamic regulation of GH secretion in the rat. J Endocrinol Invest 1996; 19: 542–7
Laron Z, Klinger B, Jensen LT, et al. Biochemical and hormonal changes induced by one week of administration of rIGF-I to patients with Laron type dwarfism. Clin. Endocrinol 1991; 35: 145–50
Klinger B, Jensen LT, Silbergeld A, et al. Insulin-like growth factor-I raises serum procollagen levels in children and adults with Laron syndrome. Clin Endocrinol 1996; 45: 423–9
Laron Z, Anin S, Klipper-Aubach Y, et al. Effects of insulin-like growth factor on linear growth, head circumference and body fat in patients with Laron-type dwarfism. Lancet 1992; 339: 1258–61
Walker JL, Van Wyk JJ, Underwood LE. Stimulation of statural growth by recombinant insulin-like growth factor I in a child with growth hormone insensitivity syndrome (Laron type). J Pediatr 1992; 121: 641–6
Klinger B, Laron Z. Renal function in Laron syndrome patients treated by insulin-like growth factor-I. Pediatr Nephrol 1994; 8: 684–8
Kaneti H, Karasik A, Klinger B, et al. Long-term treatment of Laron type dwarfs with insulin-like growth factor I increases serum insulin-like growth factor — binding protein 3 in the absence of growth hormone activity. Acta Endocrinol 1993; 128: 144–9
Rechler MM, Brown AL. Insulin-like growth factor binding proteins: gene structure and expression. Growth Regul 1992; 2: 55–68
Klinger B, Anin S, Silbergeld A, et al. Development of hyperandrogenism during treatment with insulin-like growth factor-I (IGF-I) in female patients with Laron Syndrome. Clin Endocrinol 1998; 48: 81–87
Ranke MB, Savage MO, Chatelain PG, et al. Insulin-like growth factor I improves height in growth hormone insensitivity: two years’ results. Horm Res 1995; 44: 253–64
Backeljauw PF, Underwood LE, the GHIS collaborative group. Prolonged treatment with recombinant insulin-like growth factor-I in children with growth hormone insensitivity syndrome — a clinical research center study. J Clin Endocrinol Metab 1996; 81: 3312–7
Klinger B, Laron Z. Three year IGF-I treatment of children with Laron Syndrome. J Pediatr Endocrinol Metab 1995; 8: 149–58
Guevara-Aguirre J, Rosenbloom AL, Vasconez O, et al. Two year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor-I in 22 children: comparison of two dosage levels and to GH treated GH deficiency. J Clin Endocrinol Metab 1997; 82: 629–33
Guevara-Aguirre J, Vasconez O, Martinez V, et al. A randomized, double blind, placebo-controlled trial on safety and efficacy of recombinant human insulin-like growth factor-I in children with growth hormone receptor deficiency. J Clin Endocrinol Metab 1995; 80: 1393–8
Laron Z, Klinger B. IGF-I treatment of adult patients with Laron syndrome: preliminary results. Clin Endocrinol 1994; 41: 631–8
Oliviera SB, Arnhold IJP, Phillips JA III. Treatment with recombinant IGF-I for patients with growth hormone (GH) gene deletion. [abstract no.8] Pediat Res 1997; 41: 301
Bach LA, Rechler MM. Insulin-like growth factors and diabetes. Diabetes Metab Rev 1992; 8: 229–57
Cheetham TD, Jones J, Taylor AM, et al. The effects of recombinant human insulin-like growth factor-I administration on growth hormone levels and insulin requirements in adolescents with type I (insulin dependent) diabetes mellitus. Diabetologia 1993; 36: 678–81
Cheetham TD, Clayton KL, Taylor AM, et al. The effects of recombinant human insulin-like growth factor-I on growth hormone secretion in adolescents with insulin dependent diabetes mellitus. Clin Endocrinol 1994; 40: 515–22
Bach MA, Chin E, Bondy CA. The effects of subcutaneous insulin-like growth factor-I infusion in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1994; 79: 1040–5
Cheetham TD, Connors M, Clayton K, et al. The relationship between overnight GH levels and insulin concentrations in adolescents with insulin- dependent diabetes mellitus (IDDM) and the impact of recombinant human insulin-like growth factor I (rhIGF-I). Clin Endocrinol 1997; 46: 415–24
Dunger DB, Cheetham TD, Holly JMP, et al. Does recombinant insulin-like growth factor-I have a role in the treatment of insulin-dependent diabetes mellitus during adolescence. Acta Paediatr Scand 1993; (Suppl) 388: 49–52
Dunger DB, Acerini CL, Cheetham TD, et al. How does rhIGF-I replacement improve insulin sensitivity in insulin dependent diabetes mellitus? J Pediat Endocrinol Metab 1997; 10: 117–22
Bereket A, Lang CH, Blethen SL, et al. Insulin-like growth factor binding protein-3 proteolysis in children with insulin-dependent diabetes mellitus: a possible role for insulin in the regulation of IGFBP-3 protease activity. J Clin Endocrinol Metab 1995; 80: 2282–8
Acerini CL, Patton CM, Savage MO, et al. Randomised placebo-controlled trial of human recombinant insulin-like growth factor I plus intensive insulin therapy in adolescents with insulin-dependent diabetes mellitus. Lancet 1997; 350: 1199–204
Quattrin T, Thrailkill K, Baker L, et al. Dual recombinant replacement with insulin and recombinant human insulin-like growth factor I in IDDM. Diabetes Care 1997; 20: 374–80
Thrailkill K, Quattrin T, Baker L, et al. Dual hormonal replacement therapy with insulin and recombinant human insulin-like growth factor I (IGF-I) in insulin-dependent diabetes mellitus: effects on the growth hormone/IGF/IGF- binding protein system. J Clin Endocrinol Metab 1997; 82: 1181–7
Usala A-L, Madigan T, Burguera B, et al. Brief report: treatment of insulin- resistant diabetic ketoacidosis with insulin-like growth factor I in an adolescent with insulin-dependent diabetes. N Engl J Med 1992; 327: 853–7
Longo N, Singh R, Griffin LD, et al. Impaired growth in Rabson-Mendenhall syndrome: lack of effect of growth hormone and insulin-like growth factor I. J Clin Endocrinol Metab 1994; 79: 799–805
Usala A-L, Madigan T, Burguera B, et al. High dose intravenous, but not low dose subcutaneous insulin-like growth factor-I therapy induces sustained insulin sensitivity in severely resistant type I diabetes mellitus. J Clin Endocrinol Metab 1994; 79: 435–40
Backeljauw PF, Alves C, Eidson M, et al. Effect of intravenous insulin-like growth factor I in two patients with leprechaunism. Pediatr Res 1994; 36: 749–54
Schalch DS, Turman NJ, Marcsisin VS, et al. Short-term effects of recombinant human insulin-like growth factor I on metabolic control of patients with type II diabetes mellitus. J Clin Endocrinol Metab 1993; 77: 1563–8
Young SCJ, Clemmons DR. Changes in insulin-like growth factor (IGF)- binding proteins after IGF-I injections in non-insulin-dependent diabetics. J Clin Endocrinol Metab 1994; 78: 609–14
Jabri N, Schalch DS, Schwartz SL, et al. Adverse effects of recombinant human insulin-like growth factor I in obese insulin-resistant type II diabetic patients. Diabetes 1994; 43: 369–74
Moses AC. Recombinant human insulin-like growth factor as a therapeutic agent for severe insulin resistance and type II diabetes mellitus. J Pediatr Endocrinol Metab 1997; 10: 123–30
rhIGF-I in NIDDM study group. Evidence from a dose-ranging study that recombinant insulin-like growth factor-I (rhIGF-I) effectively and safely improves glycemic control in non-insulin dependent diabetes mellitus (NIDDM) [abstract no. 94] Diabetes 1996; 45(Suppl. 2): 27A
Laron Z, Karp M. Carbohydrate metabolism in the syndrome of familial dwarfism and high plasma immunoreactive growth hormone (Laron type dwarfism). In: Podolsky S, Wiswanathan M, editors. Secondary diabetes: the spectrum of the diabetic syndrome. Nw York: Raven Press, 1980: 363–71
Laron Z, Avitzur Y, Klinger B. Carbohydrate metabolism in primary growth hormone resistance (Laron syndrome), before and during insulin-like growth factor I treatment. Metabolism 1995; 44(Suppl 4): 113–8
Laron Z, Avitzur Y, Klinger B. Carbohydrate metabolism in primary growth hormone resistance (Laron syndrome) before and during insulin-like growth factor-I treatment. J Pediatr Endocrinol Metab 1997; 10: 105–15
Tamborlane WV, Hintz RL, Bergman M, et al. Insulin-infusion-pump treatment of diabetes: influence of improved metabolic control on plasma somatomedin levels. N Engl J Med 1981; 305: 303–7
Annotations: insulin and insulin-like growth factors in diabetes mellitus. Arch Dis Child 1995; 72: 469-77
Dahlen GH. Lp(a) lipoprotein in cardiovascular disease (Review). Atherosclerosis 1994; 108: 111–26
Utennann G. The mysteries of lipoprotein(a). Rev Sci 1989; 246: 904–10
Eden S, Oscarsson J. GH and IGF-I in lipoprotein metabolism. J Pediatr Endocrinol Metab 1997; 10: 137–41
Laron Z, Wang XL, Silbergeld, et al. Growth hormone increases and insulin-like growth factor-I decreases circulating lipoprotein(a). Eur J Endocrinol 1997; 136: 377–81
Laron Z, Klinger B, Silbergeld A, et al. Opposing effects of growth hormone and insulin-like growth factor I on serum lipoprotein. J Pediatr Endocrinol Metab 1997; 10: 143–9
Hirschberg R, Kopple JD. Insulin-like growth factor I and renal function. Diabetes Rev 1995; 3: 177–95
Laron Z, Wang XL, Klinger B, et al. Growth hormone treatment increases circulating lipoprotein(a) in children with chronic renal failure. J Pediatr Endocrinol Metab 1996; 9: 533–7
Bondy CA, Lee W-H. Patterns of insulin-like growth factor and IGF receptor gene expression in the brain: functional implications. In: Raizada MK, LeRoith DL, editors. The role of insulin-like growth factors in the nervous system. Ann N Y Acad Sci 1993; 692: 33-43
Raizada MK, LeRoith DL, editors. The role of insulin-like growth factors in the nervous system. Ann N Y Acad Sci 1993; 692: 33-43
Gluckman PD, Guan J, Beilharz EJ, et al. The role of the insulin-like growth factor system in neuronal rescue. The role of insulin-like growth factors in the nervous system. In: Raizada MK, LeRoith DL, editors. The role of insulin-like growth factors in the nervous system. Ann N Y Acad Sci 1993; 692: 138-48
Bozyczko-Coyne D, Glicksman MA, Prantner JE, et al. IGF-I supports the survival and/or differentiation of multiple types of central nervous system neurons. In: Raizada MK, LeRoith DL, editors. The role of insulin-like growth factors in the nervous system. Ann N Y Acad Sci 1993; 692: 311-3
Carlsson-Skwirut C, Jornwall H, Holmgren A, et al. Isolation and characterization of varian IGF-I as well as ICF-2 from adult human brain FEBS Lett 1986; 201: 46–50
Doyle KL, Sara VR, Plenderleith MB. Localisation of insulin-like growth factor-I in spinal cord of rats following unilateral sciatic nerve transection. [abstract no. OR-24] In: 10th International Congress of Endocrinology: San Francisco, CA, USA, 1996: 459
Reynolds R, Wong V, et al. Brain-derived neurotrophic factor and eurotrophin −4/5 stimulate proliferation and c-Fos expression in cultured ligodendroglial progenitors: synergism with insulin-like growth factor-I 1997. In press
Laron Z, Pertzelan A, Karp M. Pituitary dwarfism with high serum levels of growth hormone. Isr J Med Sci 1968; 4: 883–94
Galatzer A, Aran O, Nagelberg N, et al. Cognitive and psychosocial functioning of young adults with Laron syndrome. In: Laro Z, Parks JS, editors. Lessons from Laron Syndrome (LS) 1966-1992. Pediatr Adolesc Endocrinol,Basel-New York: Karger, 1993: 53–60
Woods KA, Fraser NC, Postel-Vinay MC, et al. A homozygous splice site mutation affecting the intracellular domain of the growth hormone (GH) receptor resulting in Laron syndrome with elevated GH-binding protein. J Clin Endocrinol Metab 1996; 81: 1686–90
Laron Z, Lazar L, Galatzer A, et al. Growth hormone treatment accelerates head circumference growth in isolated GH deficiency. In: Hauspie R, Lindgren G, Falkner F, editors. Essays on Auxology. Hertfordshire, UK: Castlemead Publications, 1995: 489–95
Kranzler JH, Rosenbloom AL, Martinez V, et al. Normal intelligence with severe insulin-like growth factor I deficiency due to growth hormone receptor deficiency. A controlled study in a genetically homogenous population. J Clin Endocrinol Metab 1998; 83: 1953–8
Laron Z, Galatzer A. A comment on normal intelligence in growth hormone receptor deficiency. (Letter). J Clin Endocrinol Metab 1998; 83: December (In Press)
Lai EC, Felice KJ, Festoff BW, et al. Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. Neurology 1997; 49: 1621–30
Reid IR, Gluckman PD, Ibbertson HK. Insulin-like growth factor I and bone turnover in glucocortoid-treated and control subjects. Clin Endocrinol 1989; 30: 347–53
Rubin CD, Reed B, Sakhaee K, et al. Treating a patient with Werner syndrome and osteoporosis using recombinant human insulin-like growth factor. Ann Int Med 1994; 121: 665–8
Johansson AG, Lindh E, Blum WF, et al. Effects of growth hormone and insulin-like growth factor I in men with idiopathic osteoporosis. J Clin Endocrinol Metab 1996; 81: 44–8
Jenkins RC, Ross RJM. The use of growth hormone and insulin-like growth factor-I in catabolic states. J Pediatr Endocrinol Metab 1997; 10: 131–6
Herndon DN, Barrow RE, Kunkel KR, et al. Effects of recombinant human growth hormone on donor site healing in severely burned children. Ann Surg 1990; 212: 424–31
Gore DC, Honeycutt D, Jahoor F, et al. Effect of exogenous growth hormone on whole body and isolated limb protein kinetics in burned patients. Arch Surg 1991; 126: 38–43
Krentz AT, Koster FT, Crist DM, et al. Anthropometric, metabolic, and immunological effects of recombinant human growth hormone in AIDS and AIDS-related complex. J Acquir Immune Defic Syndr 1993; 6: 245–51
Lieberman SA, Butterfield GE, Harrison D, et al. Anabolic effects of recombinant insulin-like growth factor-I in cachectic patients with acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1994; 78: 404–10
Cioffi WG, Gore DC, Rue LC, et al. Insulin-like growth factor-I lowers protein oxidation in patients with thermal injury. Ann Surg 1994; 220: 310–9
Huang KF, Chung DH, Herndon DN. Insulin like growth factor 1 (IGF-1) reduces gut atrophy and bacterial translocation after severe burn injury. Arch Surg 1993; 128: 47–54
Tashiro T, Yamamori H, Takagi K, et al. Effects of growth hormone and insulin-like growth factor I on protein metabolism after experimental burn injury. Endocrinol Metab 1996; 3(Suppl A): 75
Shimoda N, Tashiro T, Yamamori H, et al. Effects of growth hormone and insulin-like growth factor-I on protein metabolism, gut morphology, and cell-mediated immunity in burned rats. Nutrition 1997; 13: 540–6
Goeters C, Mertes N, Tacke J, et al. Repeated administration of recombinant human insulin-like growth factor-I in patients after gastric surgery. Ann Surg 1995; 222: 646–53
Miell JP, Taylor AM, Jones J, et al. Administration of human recombinant insulin-like growth factor-I to patients following major gastrointestinal surgery. Clin Endocrinol 1992; 37: 542–51
Muta K, Krantz S, Bondourant MC, et al. Distinct roles of erythropoietin, insulin-like growth factor I and stem cell factor in the development of erythroid progenitor cells. J Clin Invest 1992; 94: 34–43
Merchav S, Silvian-Drachsler I, Tatarsky I, et al. Comparative studies of the erythroid-potentiating effects of biosynthetic human insulin-like growth factors I and II. J Clin Endocrinol Metab 1992; 74: 447–52
Zegers BJM, Merchav S. Growth hormone and insulin-like growth factors in haemopoiesis, lymphopoiesis and immune function. Endocrinol Metab 1996; 3(Suppl. A): 105–9
Merchav S, Tatarksy I, Hochberg Z. Enhancement of human granulopoiesis in vitro by biosynthetic insulin-like growth factor I/somatomedin C and human growth hormone. J Clin Invest 1988; 81: 791–7
Merchav S, Lake M, Skottner A. Comparative studies of the granulopoietic enhancing effects of biosynthetic human insulin-like growth factors I and II. J Cell Physiol 1993; 157: 178–83
Clark R, Strasser J, McCabe S, et al. Insulin-like growth factor-I stimulation of lymphoporesis. J Clin Invest 1993; 92: 540–8
Landreth KS, Narayanan R, Dorshkind K. Insulin-like growth factor-I regulates pro-B cell differentiation. Blood 1992; 80: 1207–12
Steeb CB, Shoubridge CA, Tivey DR et al. Systemic infusion of IGF-I or LR3 IGF-I stimulates visceral organ growth and proliferation of gut tissues in suckling rats. Am J Physiol 1997; 272 (Gastointest Liver Physiol 35): G522–33
Fholenhag K, Arrhenius-Nyberg V, Sjogren I, et al. Effects of insulin-like growth factor I (IGF-I) on the small intestine: a comparison between oral and subcutaneous administration in the weaned rat. Growth Factors 1997; 14: 81–8
Wolf E, Jehle PM, Weber MM, et al. Human insulin-like growth factor I (IGF-I) produced in the mammary glands of transgenic rabbits: yield, receptor binding, mitogenic activity, and effects on IGF-I binding proteins. Endocrinology 1997; 138: 307–13
Wang YZ, Wong YC. Sex hormone-induced prostatic carcinogenesis in the noble rat: the role of insulin-like growth factor-I (IGF-I) and vascular endothelial growth factor (VEGF) in the development of prostate cancer. Prostate 1998; 35: 165–77
Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998; 279: 563–6
Fleming RYD, Rutan RL, Jahoor F, et al. Effect of recombinant human growth hormone on catabolic hormones and free fatty acids following thermal injury. J Trauma 1992; 32: 698–703
Kupfer SR, Underwood LE, Baxter RC, et al. Enhancement of the anabolic effect of growth hormone and insulin-like growth factor I by use of both agents simultaneously. J Clin Invest 1993; 91: 391–6
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Laron, Z. Somatomedin-1 (Recombinant Insulin-Like Growth Factor-1). BioDrugs 11, 55–70 (1999). https://doi.org/10.2165/00063030-199911010-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00063030-199911010-00006